Susquehanna International Group’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-9,350
Closed -$46.8K 13639
2024
Q3
$46.8K Sell
9,350
-1,420
-13% -$9.22K ﹤0.01% 11407
2024
Q2
$71.1K Buy
10,770
+7,410
+221% +$50.4K ﹤0.01% 11238
2024
Q1
$37K Sell
3,360
-38,130
-92% -$413K ﹤0.01% 11651
2023
Q4
$560K Buy
41,490
+4,260
+11% +$69.1K ﹤0.01% 8376
2023
Q3
$808K Sell
37,230
-1,170
-3% -$37.5K ﹤0.01% 7127
2023
Q2
$1.48M Buy
38,400
+1,280
+3% +$45.1K ﹤0.01% 5798
2023
Q1
$1.03M Buy
37,120
+35,523
+2,224% +$1.2M ﹤0.01% 6739
2022
Q4
$51.9K Sell
1,597
-856
-35% -$62.4K ﹤0.01% 11374
2022
Q3
$294K Sell
2,453
-623
-20% -$112K ﹤0.01% 9848
2022
Q2
$538K Sell
3,076
-520
-14% -$110K ﹤0.01% 8085
2022
Q1
$1.04M Sell
3,596
-3,789
-51% -$1.44M ﹤0.01% 7003
2021
Q4
$3.86M Buy
7,385
+4,359
+144% +$3.13M ﹤0.01% 4192
2021
Q3
$1.15M Buy
3,026
+2,938
+3,339% +$1.26M ﹤0.01% 7208
2021
Q2
$79K Buy
88
+30
+52% +$22.9K ﹤0.01% 12182
2021
Q1
$69K Buy
+58
New +$80K ﹤0.01% 11973

Susquehanna International Group's BIOR Position: Q1 2024 in Review

Susquehanna International Group sold out of Biora Therapeutics, Inc. Common Stock (BIOR) in Q1 2024, closing a stake of 5,085 shares — an estimated $55K sold.

Susquehanna International Group first reported a position in BIOR in Q1 2021 and held it in 11 quarters. The position peaked at $3.23M in Q4 2021. 27 funds tracked by Wall St. Rank hold BIOR as of Q1 2024.

  • Susquehanna International Group reported no remaining Biora Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 5,085 Biora Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $55K.
  • Susquehanna International Group first reported a position in Biora Therapeutics, Inc. Common Stock in Q1 2021 and held it in 11 quarters.
  • Susquehanna International Group's Biora Therapeutics, Inc. Common Stock position peaked at $3.23M in Q4 2021.
  • 27 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.